In the attempt of identifying the immune correlates of chemo-immunotherapy efficacy, we analyzed the humoral immune response against HER-2 antigen in transgenic mice receiving CTX + ACT/IS therapy, that could account for long-term resistance to spontaneous tumor development. The gene discussed is ERBB2; the disease is neoplasm.